Core Viewpoint - The announcement highlights that China National Pharmaceutical Group Modern (国药现代) has received approval from the National Medical Products Administration for the registration of Fumaric Acid Quetiapine Sustained-Release Tablets, indicating a significant advancement in the company's pharmaceutical offerings [1] Group 1 - The product, Fumaric Acid Quetiapine Sustained-Release Tablets, is classified as an atypical antipsychotic medication [1] - It is primarily used for the treatment of schizophrenia and bipolar disorder, aiming to stabilize mood, reduce hallucinations, and improve cognitive function [1] - The medication is designed to assist patients in regaining normal cognitive and social functions [1]